FDA approves first drug shown to extend life in severe Niemann-Pick disease
Life Sciences
Tuesday, November 17, 2026
- Updated Nov 17, 2026 15:42
The US Food and Drug Administration on Tuesday approved Beren Therapeutics' Lembaz (adrabetadex), the first treatment shown to reduce the risk of death in patients whose Niemann-Pick disease type C symptoms began before age 6.
Why it matters: Niemann-Pick disease type C affects an estimated 1 in 150,000 people and its infantile-onset form is the most severe; the two previously approved therapies have not been shown to reduce the risk of death and carry age and weight limits that exclude the youngest patients.
Data as of US Food and Drug Administration news release of November 17, 2026, read in full from fda.gov; all approval terms, survival figures and safety wording are the agency's own. Developing item.
The US Food and Drug Administration on Tuesday approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C live longer. Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg and whose neurological symptoms began before age 6, the infantile-onset form of the disease, and it is given by a trained healthcare provider as an injection into the spinal canal every two weeks.
The agency based the approval on survival data from 36 treated patients across three clinical studies and an expanded access program: patients on Lembaz had a 55 percent reduction in the risk of death against a matched external control group, with median survival of 8.5 years against 4.9 years for controls. The drug carries a boxed warning for hearing impairment, including permanent hearing loss, and the FDA granted the approval to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.
Sources
- FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer - US Food and Drug Administration - 2026-11-17